CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers
Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and...
2026-06-08 7:00 AM EDT
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation. The Company views this milestone as part of its broader strategy to build research-driven...
2026-06-01 7:00 AM EDT
CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio
Houston, Texas--(Newsfile Corp. - January 21, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today that it is in the evaluation stage of a potential financing transaction under Regulation A (Reg A), in an estimated amount in the order of $1,000,000, subject to change, internal review, and applicable market and compliance conditions. CBIH clarifies that this communication reflects a...
2026-01-21 7:00 AM EST
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding. CBIH confirms receipt of a communication from the Centers for Medicare...
2026-01-12 7:00 AM EST
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Executive Order directed...
2026-01-05 7:00 AM EST
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died from...
2025-12-29 7:00 AM EST
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighteen years of navigating...
2025-12-22 7:00 AM EST
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III. CBIH believes that, if the process moves forward, it could represent one of the most consequential...
2025-12-15 7:00 AM EST
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners. As age is a key determinant of reproductive outcomes—and first births are...
2025-10-13 7:00 AM EDT
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder...
2025-10-06 7:00 AM EDT
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas healthcare is experiencing a historic breakthrough with the approval of House Bill 46 (HB 46). Signed into law on June 21, 2025, by Governor Greg Abbott, the expansion of the Texas Compassionate Use Program (TCUP) will cover chronic pain, PTSD, and degenerative neurological conditions, among...
2025-09-29 7:00 AM EDT
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
Houston, Texas--(Newsfile Corp. - November 4, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to announce the appointment of Mr. Charles Tamburello as a new member of the board of directors. His extensive experience in the public markets, which spans nearly three decades, will play a crucial role in driving the company's mergers and acquisitions (M&A) strategy forward. Mr. Tamburello has been instrumental in the success of hundreds of public and private...
2024-11-04 8:00 AM EST
CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings
Houston, Texas--(Newsfile Corp. - October 28, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the ticker symbol CBIH has reached a major milestone in expanding its patent portfolio, filing six utility non-provisional applications for cannabinoid-based therapies that address underserved medical conditions. These patents cover therapeutic innovations for conditions such as pancreatic cancer (No. 18/905,128), breast cancer (No. 18/918,386),...
2024-10-28 8:00 AM EDT
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications. From our desks - Rosangel Andrades and Jennifer Salguero. In the realm of medicine, patent requirements...
2024-07-08 8:00 AM EDT
CBIH Submits Groundbreaking Cannabis Patents for Breast and Pancreatic Cancer Treatments
Houston, Texas--(Newsfile Corp. - July 1, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration. Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic...
2024-07-01 8:00 AM EDT
CBIH's Recently Appointed Director Unveils Groundbreaking Product Strategies and Potential Partnership with Industry Leader
Houston, Texas--(Newsfile Corp. - June 24, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to introduce the groundbreaking strategies formulated by its freshly appointed Treasurer and Director, Mr. John Jones, who has facilitated a series of insightful discussions and established official communications between CBIH and a pioneering company in innovative product and packaging solutions for globally recognized brands. As CBIH prepares for the manufacturing and...
2024-06-24 8:00 AM EDT
CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment
Houston, Texas--(Newsfile Corp. - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California. StoneBridge's assessment highlights CBIH's formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH's...
2024-06-17 8:00 AM EDT
Vita Biotech Retains CBIH Services for Clinical Studies
Houston, Texas--(Newsfile Corp. - June 5, 2024) - Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTC Pink: CBIH), to fund the clinical data collection efforts of CBIH's rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity. Through this strategic alliance, Vita Biotech will act as a financial subsidiary and...
2024-06-05 8:00 AM EDT
Cannabis Bioscience International Holdings Engages StoneBridge Advisory for Comprehensive Company Valuation
Houston, Texas--(Newsfile Corp. - May 29, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) announces the engagement of StoneBridge Advisory (stonebridgema.com) for CBIH's company valuation. The Colorado-based firm specializes in business valuations as well as mergers and acquisitions, boasting over three decades of experience in the industry. They represent businesses for sale, and their expertise lies in in-depth professional valuation reports that are IRS Revenue Ruling...
2024-05-29 8:00 AM EDT
CBIH Engages Prestigious Law Firm for its First Patent Applications
Houston, Texas--(Newsfile Corp. - May 20, 2024) - Cannabis Bioscience International Holdings(OTC Pink: CBIH), utilizing robust methodologies to safeguard its intellectual property and establish a well-defined company portfolio, has engaged Vereb Law Group PLLC (www.vereblawgroup.com), a reputable law firm with headquarters in Houston, which handles all aspects of intellectual property litigation, including matters related to patents, trademarks, copyrights, and trade secrets. CBIH...
2024-05-20 8:00 AM EDT